NASDAQ:ARGX

argenx Stock Forecast, Price & News

$313.67

-2.14 (-0.68 %)

(As of 06/23/2021 02:05 PM ET)

Add

Compare

Today's Range

$310.42

▼

$316.20

50-Day Range

$257.11

▼

$319.92

52-Week Range

$212.66

▼

$382.15

Volume1,262 shs

Average Volume195,195 shs

Market Capitalization$16.09 billion

P/E RatioN/A

Dividend YieldN/A

Beta0.92

30 days | 90 days | 365 days | Advanced Chart

Receive ARGX News and Ratings via Email

Sign-up to receive the latest news and ratings for argenx and its competitors with MarketBeat's FREE daily newsletter.

About argenx

argenx SE, a clinical-stage biotechnology company, focuses on developing antibody-based therapies for the treatment of autoimmune diseases, hematology, and cancer. It is developing its lead product candidate, efgartigimod, for the treatment of patients with myasthenia gravis; immune thrombocytopenia in Phase III; pemphigus vulgaris in Phase III; chronic inflammatory demyelinating polyneuropathy in Phase III; and ENHANZE SC in pre-clinical stages. The company is also developing cusatuzumab in Phase II clinical stage in hematological cancer indications; ARGX-117 in phase I clinical trial with therapeutic potential in both orphan and large autoimmune inflammatory diseases; and preclinical products, including ARGX-118 for airway inflammation. Its partnered product candidates include ARGX-112 for treating skin inflammation, ARGX-116 for the treatment of dyslipidemia, and ARGX-115 for cancer immunotherapy, which are in Phase I clinical stages; and ARGX-114 for treating fibrosisand ARGX-119 for treating neuromuscular indications, which are in preclinical stage. The company has strategic partnership with AbbVie S.Ã.R.L. and LEO Pharma A/S; and collaboration agreement with Cilag GmbH International, Staten Biotechnology B.V., and Shire International GmbH. argenx SE was incorporated in 2008 and is based in Breda, the Netherlands.

Zacks: Brokerages Anticipate argenx SE (NASDAQ:ARGX) Will Announce Earnings of -$3.38 Per Share
June 20, 2021 | americanbankingnews.com

Where argenx Stands With Analysts - Benzinga - Benzinga
June 18, 2021 | benzinga.com

UBS Group Initiates Coverage on argenx (NASDAQ:ARGX)
June 18, 2021 | americanbankingnews.com

argenx announces publication of Phase 3 ADAPT trial results - GlobeNewswire
June 17, 2021 | globenewswire.com

Argenx reports late-stage efgartigimod trial results for myasthenia gravis in The Lancet Neurology - Seeking Alpha
June 17, 2021 | seekingalpha.com

argenx announces publication of Phase 3 ADAPT trial results of efgartigimod for the treatment of generalized myasthenia gravis in The Lancet Neurology
June 16, 2021 | finance.yahoo.com

Argenx's drug effective against muscle-weakening disease myasthenia gravis
June 16, 2021 | finance.yahoo.com

Argenx Is a Biotech Stock With Big Potential
June 15, 2021 | finance.yahoo.com

argenx (ARGX) to Regain AML Candidate After J&J's Dismissal - Yahoo Finance
June 9, 2021 | finance.yahoo.com

Biotech Stock Roundup: BIIB's Drug Approval, ALXN Drug Label Expansion & More
June 9, 2021 | finance.yahoo.com

See More Headlines

Industry, Sector and Symbol

Stock Exchange NASDAQ
Industry Biological products, except diagnostic
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:ARGX
Previous Symbol
CUSIPN/A
CIK1697862
Webwww.argenx.com
Phone329-310-3400
Employees336
Year FoundedN/A

Sales & Book Value

Annual Sales$41.60 million
Price / Sales386.85
Cash FlowN/A
Price / Cash FlowN/A
Book Value$32.92 per share
Price / Book9.53

Profitability

EPS (Most Recent Fiscal Year)($13.30)
Net Income$-604,190,000.00
Net Margins-298.93%
Return on Equity-50.37%
Return on Assets-38.67%

Debt

Price-To-Earnings

Miscellaneous

Outstanding Shares51,306,000
Market Cap$16.09 billion
Next Earnings Date7/30/2021 (Estimated)
OptionableOptionable

MarketRank^™

Overall MarketRank^™

1.13 out of 5 stars

Medical Sector

1034th out of 2,105 stocks

Biological Products, Except Diagnostic Industry

145th out of 198 stocks

2.3 Analyst's Opinion

Consensus Rating
argenx has received a consensus rating of Buy. The company's average rating score is 2.65, and is based on 11 buy ratings, 6 hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $332.15, argenx has a forecasted upside of 6.6% from its current price of $311.70.
Amount of Analyst Coverage
argenx has been the subject of 7 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

2.5 Community Rank

Outperform Votes
argenx has received 522 “outperform” votes. (Add your “outperform” vote.)
Underperform Votes
argenx has received 515 “underperform” votes. (Add your “underperform” vote.)
Community Sentiment
argenx has received 50.34% “outperform” votes from our community.

MarketBeat's community ratings are surveys of what our community members think about argenx and other stocks. Vote “Outperform” if you believe ARGX will outperform the S&P 500 over the long term. Vote “Underperform” if you believe ARGX will underperform the S&P 500 over the long term. You may vote once every thirty days.

0.0 Dividend Strength

Dividend Yield
argenx does not currently pay a dividend.
Dividend Growth
argenx does not have a long track record of dividend growth.

0.8 Company Ownership

Insider Buying vs. Insider Selling
In the past three months, argenx insiders have not sold or bought any company stock.
Percentage Held by Institutions
55.50% of the stock of argenx is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

0.0 Earnings and Valuation

Earnings Growth
Earnings for argenx are expected to decrease in the coming year, from ($12.98) to ($15.66) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of argenx is -25.72, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of argenx is -25.72, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
argenx has a P/B Ratio of 9.47. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

argenx (NASDAQ:ARGX) Frequently Asked Questions

Is argenx a buy right now?

17 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for argenx in the last twelve months. There are currently 6 hold ratings and 11 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" argenx stock.
View analyst ratings for argenx or view top-rated stocks.

What stocks does MarketBeat like better than argenx?

Wall Street analysts have given argenx a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but argenx wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

When is argenx's next earnings date?

argenx is scheduled to release its next quarterly earnings announcement on Friday, July 30th 2021.
View our earnings forecast for argenx.

How were argenx's earnings last quarter?

argenx SE (NASDAQ:ARGX) announced its quarterly earnings data on Friday, May, 14th. The company reported ($0.81) earnings per share for the quarter, topping the Zacks' consensus estimate of ($3.14) by $2.33. The firm had revenue of $167.42 million for the quarter, compared to the consensus estimate of $39.04 million. argenx had a negative net margin of 298.93% and a negative trailing twelve-month return on equity of 50.37%.
View argenx's earnings history.

How has argenx's stock been impacted by Coronavirus (COVID-19)?

argenx's stock was trading at $133.81 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, ARGX shares have increased by 134.3% and is now trading at $313.58.
View which stocks have been most impacted by COVID-19.

What price target have analysts set for ARGX?

17 Wall Street analysts have issued 12-month target prices for argenx's stock. Their forecasts range from $250.00 to $430.00. On average, they expect argenx's stock price to reach $332.15 in the next twelve months. This suggests a possible upside of 5.9% from the stock's current price.
View analysts' price targets for argenx or view top-rated stocks among Wall Street analysts.

Who are argenx's key executives?

argenx's management team includes the following people:

Mr. Timothy Van Hauwermeiren M.B.A., M.Sc., MSc, EMBA, CEO & Exec. Director (Age 49, Pay $1.22M)
Mr. Eric Castaldi, Chief Financial Officer (Age 57)
Mr. R. Keith Woods, Chief Operating Officer (Age 53)
Prof. Hans de Haard, Chief Scientific Officer (Age 61)
Mr. Dirk Marcel Leon Beeusaert L.L.M., Gen. Counsel (Age 57)
Mr. Arjen Lemmen M.Sc., VP of Corp. Devel. & Strategy (Age 36)
Mr. Marc Schorpion, Global Head of HR (Age 63)
Dr. David L. Lacey, Advisor (Age 69, Pay $60.82k)
Dr. Wim Parys M.D., Chief Medical Officer (Age 61)
Ms. Andria Wilk, Global Head of Quality (Age 48)

Who are some of argenx's key competitors?

Some companies that are related to argenx include BioNTech (BNTX), Biogen (BIIB), Seagen (SGEN), Novozymes A/S (NVZMY), Bio-Techne (TECH), Novavax (NVAX), Repligen (RGEN), QIAGEN (QGEN), CRISPR Therapeutics (CRSP), Neurocrine Biosciences (NBIX), Denali Therapeutics (DNLI), Fate Therapeutics (FATE), Acceleron Pharma (XLRN), Exelixis (EXEL) and Vir Biotechnology (VIR).
View all of ARGX's competitors.

What other stocks do shareholders of argenx own?

Based on aggregate information from My MarketBeat watchlists, some companies that other argenx investors own include Galapagos (GLPG), Kohl's (KSS), AcelRx Pharmaceuticals (ACRX), Gilead Sciences (GILD), Neurocrine Biosciences (NBIX), Pfizer (PFE), CRISPR Therapeutics (CRSP), Fate Therapeutics (FATE), NVIDIA (NVDA) and Sarepta Therapeutics (SRPT).

When did argenx IPO?

(ARGX) raised $65 million in an IPO on Thursday, May 18th 2017. The company issued 3,600,000 shares at $18.18 per share. Cowen and Company and Piper Jaffray acted as the underwriters for the IPO and JMP Securities and Wedbush PacGrow were co-managers.

What is argenx's stock symbol?

argenx trades on the NASDAQ under the ticker symbol "ARGX."

Who are argenx's major shareholders?

argenx's stock is owned by many different retail and institutional investors. Top institutional shareholders include Price T Rowe Associates Inc. MD (11.29%), Artisan Partners Limited Partnership (5.60%), Baker BROS. Advisors LP (2.18%), Bellevue Group AG (1.86%), Redmile Group LLC (1.66%) and Jennison Associates LLC (1.40%).

Which institutional investors are selling argenx stock?

ARGX stock was sold by a variety of institutional investors in the last quarter, including Lord Abbett & CO. LLC, Hillhouse Capital Advisors LTD., Franklin Resources Inc., Redmile Group LLC, Ameriprise Financial Inc., Eaton Vance Management, Renaissance Technologies LLC, and Millennium Management LLC.

Which institutional investors are buying argenx stock?

ARGX stock was bought by a variety of institutional investors in the last quarter, including Price T Rowe Associates Inc. MD, Artisan Partners Limited Partnership, Jennison Associates LLC, BVF Inc. IL, BlackRock Inc., TimesSquare Capital Management LLC, Clearbridge Investments LLC, and Janus Henderson Group PLC.

How do I buy shares of argenx?

Shares of ARGX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is argenx's stock price today?

One share of ARGX stock can currently be purchased for approximately $313.58.

How much money does argenx make?

argenx has a market capitalization of $16.09 billion and generates $41.60 million in revenue each year. The company earns $-604,190,000.00 in net income (profit) each year or ($13.30) on an earnings per share basis.

How many employees does argenx have?

argenx employs 336 workers across the globe.

What is argenx's official website?

The official website for argenx is www.argenx.com.

Where are argenx's headquarters?

argenx is headquartered at Willemstraat 5, Breda P7, 4811 AH.

How can I contact argenx?

argenx's mailing address is Willemstraat 5, Breda P7, 4811 AH. The company can be reached via phone at 329-310-3400 or via email at [email protected]

This page was last updated on 6/23/2021 by MarketBeat.com Staff

30 Days of MarketBeat All Access for $1.00

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here